Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-23

Study Completion Date

2018-12-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD expansion cohort(s). Approximately 30-60 patients are expected to be enrolled in the overall study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

NCT02504333

Metastatic Pancreatic Adenocarcinoma

COMPLETED PHASE1/PHASE2

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

NCT02207465

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

ACTIVE_NOT_RECRUITING PHASE1

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

NCT03450018

Metastatic Pancreatic Ductal Adenocarcinoma

TERMINATED PHASE1/PHASE2

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

NCT02570711

Metastatic Pancreatic Cancer

TERMINATED PHASE2

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

NCT02244489

Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has 2 parts:

• Part A (Dose-Escalation Cohorts): Consecutive cohorts of patients will receive escalating doses of oral palbociclib in combination with intravenous nab-P in 28-day cycles, in order to estimate the MTD(s) of the combination. The starting doses will be 75 mg palbociclib, and 100 mg/m2 nab-P. The observation period for dose-limiting toxicities (DLTs) will be from Day 1 to Day 28. Pharmacokinetic (PK) and pharmacodynamic (PD) properties of palbociclib and nab-P will also be assessed. Up to approximately 30 patients will be enrolled. The criteria for dose escalation will be based on a modified toxicity probability interval (mTPI) method.

• Part B \[MTD Expansion Cohort(s)\]: When the MTD(s) of palbociclib plus nab-P has been estimated with confidence, enrollment will proceed into 1 or 2 MTD expansion cohort(s) of up to 20 patients each at the MTD(s). The objective of the MTD expansion cohort(s) will be to provide additional information on safety, tolerability, biomarkers, PD activity, and PK/PD relationship for the combination regimen in order to determine the RP2D. The MTD expansion cohort(s) will only enroll patients who have not received previous treatment for their metastatic disease in order to evaluate preliminary activity of the combination in the target patient population.

All patients (in Part A and B) will receive nab-P intravenously once weekly for 3 weeks out of each 28-day cycle. Palbociclib oral dosing will be once daily on Days 1-21 of each 28-day cycle. To allow for PK evaluation of nab-P administered alone, nab-P will be administered on Day -2 for Cycle 1 only. Subsequent cycles will administer both nab-P and palbociclib on Day 1. Alternate dosing schedules for palbociclib may be explored based on emerging PK, PD, and safety data.

Patients will be treated as long as they are clinically benefiting from investigational product without unacceptable toxicity, objective disease progression, or withdrawal of consent. A modified visit schedule will be implemented for patients who are on investigational product for more than 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Pancreatic Ductal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Palbociclib + Nab-Paclitaxel

Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.

Group Type EXPERIMENTAL

Palbociclib

Intervention Type DRUG

Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.

Nab-Paclitaxel

Intervention Type DRUG

Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Palbociclib

Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.

Intervention Type DRUG

Nab-Paclitaxel

Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ibrance Abraxane

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically-confirmed metastatic pancreatic ductal adenocarcinoma.
* Availability of a tumor tissue specimen. If no archived tumor tissue is available, then a de novo biopsy is required for patient participation.
* Karnofsky Performance Status 70 or greater.
* Adequate Bone Marrow, Renal, and Liver Function.

Exclusion Criteria

* Prior treatment with a CDK 4/6 inhibitor.
* Prior treatment with nab-P for the treatment of metastatic disease.
* Patients with known CNS metastases, carcinomatous meningitis, or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth.
* Diagnosis of any other malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
* QTc \>480 msec, or family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.
* Uncontrolled electrolyte disorders.
* Cardiac or pulmonary disorders within 6 months of enrollment.
* Known human immunodeficiency virus infection.
* History of interstitial lung disease or pneumonitis.
* Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-P.
* Difficulty swallowing capsules or requirement for a feeding tube.
* Previous high-dose chemotherapy requiring stem cell rescue.
* Pregnant female patients; breastfeeding female patients; male patients with partners currently pregnant.
* Active inflammatory or other gastrointestinal disease,
* Active bleeding disorder in the past 6 months.
* Patients treated within the last 7 days prior to the start of IP with strong/moderate CYP3A4 inhibitors, strong/moderate CYP3A4 inducers, CYP2C8 inhibitors, strong/moderate CYP2C8 inducers, or drugs that are known to prolong the QT interval.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Scottsdale Healthcare Hospitals DBA HonorHealth

Scottsdale, Arizona, United States

Site Status

Virginia G. Piper Cancer Pharmacy

Scottsdale, Arizona, United States

Site Status

UC San Diego Medical Center - La Jolla (Thornton Hospital)

La Jolla, California, United States

Site Status

UC San Diego Moores Cancer Center - Investigational Drug Services

La Jolla, California, United States

Site Status

UC San Diego Moores Cancer Center

La Jolla, California, United States

Site Status